We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cascadian Therapeutics, Inc. (delisted) | NASDAQ:CASC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.02 | 7.15 | 9.97 | 0 | 01:00:00 |
|
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/02938d7b-513e-467d-b9af-44a422fc2a16
November 7-8, 2017Boston Biotech Conferences NY/NJ CEO, Apella at Alexandria Center, NY, NYPanel: State of the Markets: Biotech and PharmaMore information on the conference can be found at http://bbbiotechconference.com/ceo-meetings.php
November 13-14, 2017YJP CEO Europe Forum in Berlin will feature a Healthcare Innovation SymposiumPanel: Transitioning from an R&D Company to a Commercial VentureMore information on YJP and this meeting can be found at http://access.yjp.org/e/er4ka_4
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule kinase inhibitor that is highly selective for HER2 and the Company’s lead product in development for the treatment of HER2 overexpressing cancers. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.
Investor and Media Contact:Monique GreerCascadian Therapeutics206-801-2107mgreer@cascadianrx.com
1 Year Cascadian Therapeutics, Inc. Chart |
1 Month Cascadian Therapeutics, Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions